Jazz Pharmaceuticals Plc Stock Price, News & Analysis

Jazz Pharmaceuticals and Zymeworks announced that Jazz has exercised its option to continue exclusive rights for the development and commercialization of zanidatamab, following positive clinical data from the HERIZON-BTC-01 trial in biliary tract cancers. The trial showed a 41.3% objective response rate among patients with HER2-amplified disease. Jazz will pay Zymeworks $325 million and may owe up to $1.76 billion in future milestone payments. Zanidatamab aims to provide HER2-targeted therapy for challenging cancers, currently lacking approved treatments.

Jazz Pharmaceuticals (Nasdaq: JAZZ) announced six presentations on its epilepsy treatment, Epidiolex (cannabidiol), at the 2022 American Epilepsy Society (AES) annual meeting from December 2-6, 2022, in Nashville, TN. Key highlights include long-term Phase 3 trial results showing significant seizure reduction for tuberous sclerosis complex and caregiver-reported improvements in seizure and non-seizure outcomes for patients with Lennox-Gastaut and Dravet syndromes. The data underscores Epidiolex as a crucial option for patients with significant unmet needs in epilepsy treatment.

Jazz Pharmaceuticals announced FDA approval for a new intramuscular dosing schedule for Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) to treat acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in patients one month or older with hypersensitivity to E. coli-derived asparaginase. The approval allows for a Monday/Wednesday/Friday dosing option, enhancing treatment flexibility. Clinical trial data indicated a positive benefit-to-risk profile. Rylaze has orphan drug designation and is also recognized in the National Comprehensive Cancer Network guidelines.

Stand Up To Cancer, in partnership with Jazz Pharmaceuticals, has launched a new public service announcement (PSA) to raise awareness about small cell lung cancer, particularly in Black and Hispanic communities. The PSA, available in both English and Spanish, focuses on the importance of early screening to improve survival rates, as these communities face significant disparities in diagnosis. Jazz is also supporting SU2C's Catalyst program, which funds research for new treatments in oncology.

Jazz Pharmaceuticals reported its Q3 2022 financial results, achieving total revenues of $940.7 million, a 12% increase year-over-year. The company raised its 2022 revenue guidance mid-point to $3.65 billion. Key performance drivers included strong adoption of Xywav and Epidiolex, with Xywav sales up 67% to $255.9 million. The company continues to expand its pipeline with new clinical trials, including JZP815 and suvecaltamide. Despite a GAAP net loss of $19.6 million, adjusted net income rose to $370.4 million.

On November 3, 2022, Jazz Pharmaceuticals (Nasdaq: JAZZ) announced the presentation of 13 abstracts at the American Society of Hematology (ASH) Annual Meeting from December 10-13, 2022. The research will feature findings on Rylaze^®, Vyxeos^®, and Defitelio^®. Notable highlights include a Phase 2/3 trial demonstrating the efficacy and safety of intravenous Rylaze in patients with Acute Lymphoblastic Leukemia. Jazz emphasized its commitment to advancing oncology solutions for patients with rare forms of leukemia.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will participate in three investor conferences this November. The Jefferies London Healthcare Conference is on November 15, 2022 at 5:20 a.m. ET. The 5th Annual Evercore ISI HealthCONx Conference follows on November 29, 2022 at 1:50 p.m. ET. Finally, the Piper Sandler 34th Annual Healthcare Conference will occur on November 30, 2022 at 12:00 p.m. ET. Audio webcasts of the presentations will be available on their website, archived for 30 days.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will disclose its 2022 Q3 financial results on November 9, 2022, after U.S. market close. A live audio webcast will follow at 4:30 p.m. ET, providing an analysis of the results along with a business update. Interested participants are encouraged to register ahead of time for the event. Jazz Pharmaceuticals focuses on developing transformative medicines in neuroscience and oncology for patients with serious diseases, and it operates in nearly 75 countries.